Transaldolase Deficiency and Associated Metabolic Disorders

Transaldolase deficiency is a rare inborn error of metabolism affecting the non-oxidative branch of the pentose phosphate pathway. Biallelic mutations in the TALDO1 gene result in impaired conversion of sedoheptulose-7-phosphate and glyceraldehyde-3-phosphate, leading to reduced generation of NADPH and accumulation of sugar phosphates. Clinically, patients present with a multisystem disorder characterised by intrauterine growth restriction, dysmorphic features, anaemia, thrombocytopaenia and progressive liver disease, often accompanied by renal tubulopathy and endocrine abnormalities. Disease onset ranges from prenatal demise to late childhood. Pathophysiological mechanisms include oxidative stress, disrupted redox balance and altered nucleotide and lipid biosynthesis. Genotype–phenotype correlations remain incompletely defined, though some variants are associated with more severe hepatic involvement. Treatment approaches centre on supportive care, antioxidant supplementation (notably N-acetylcysteine) and, in selected cases, liver transplantation. Emerging evidence also links transaldolase haploinsufficiency to heightened susceptibility to drug-induced liver injury and carcinogenesis.

Research from Nature Portfolio

Recent studies have uncovered fundamental aspects of transaldolase regulation and its wider metabolic impact. High-resolution analyses revealed that TALDO1 yields two translational isoforms distinguished by an N-terminal extension that directs one form into the nucleus via importin-mediated transport while the other remains cytoplasmic. This subcellular partitioning fine-tunes global metabolite levels—including tricarboxylic acid cycle intermediates and nucleotide precursors—without compromising core pentose phosphate pathway flux. Complementary systems-level investigations using quantitative intracellular metabolomics and kinetic-space modelling have reconstructed the regulatory architecture of pentose phosphate enzymes in proliferating cells. These approaches have demonstrated that post-transcriptional mechanisms selectively modulate enzyme activities, offering new avenues for interventions in disorders of redox imbalance.

Transaldolase Deficiency and Associated Metabolic Disorders publication trend

The graph below shows the total number of articles in transaldolase deficiency and associated metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Pentose phosphate pathway: A metabolic route parallel to glycolysis that generates NADPH and ribose-5-phosphate for biosynthesis and antioxidant defence.

Transaldolase: An enzyme in the non-oxidative branch of the pentose phosphate pathway that transfers three-carbon sugar units between sugar-phosphate substrates.

NADPH: Reduced nicotinamide adenine dinucleotide phosphate, a key cofactor for reductive biosynthesis and maintenance of cellular redox balance.

Haploinsufficiency: A genetic state in which loss of one functional gene copy leads to insufficient protein activity to sustain normal physiology.

Genotype–phenotype correlation: The relationship between specific genetic variants and the clinical characteristics they produce.

References

1. Clinical, biochemical, and molecular overview of transaldolase deficiency and evaluation of the endocrine function: Update of 34 patients. Journal of Inherited Metabolic Disease (2019).
2. Two isoforms of TALDO1 generated by alternative translational initiation show differential nucleocytoplasmic distribution to regulate the global metabolic network. Scientific Reports (2016).
3. The space of enzyme regulation in HeLa cells can be inferred from its intracellular metabolome. Scientific Reports (2016).
4. Transaldolase haploinsufficiency in subjects with acetaminophen‐induced liver failure. Journal of Inherited Metabolic Disease (2020).
5. Prenatal Diagnosis of Fetus With Transaldolase Deficiency Identifies Compound Heterozygous Variants: A Case Report. Frontiers in Genetics (2022).